Serological Influences on Dry Eye: Insights from the Sjögren's International Collaborative Clinical Alliance
Ophthalmology Science · 2025-11 · 5 (6) · 100843
DOI: 10.1016/j.xops.2025.100843 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmology Science, 2025-11. Verfasst von Chloe Shields und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Miami Miller School of Medicine, Miami, Florida. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Eye Institute, Sjogrens Syndrome Foundation, Research to Prevent Blindness.
Abstract (Originalsprache)
Purpose
To define associations between serologies, specifically Sjögren syndrome-related antigen A (SSA) antibody and immunoglobulin (Ig) levels, on ocular profiles in patients enrolled in the Sjögren's International Collaborative Clinical Alliance (SICCA) cohort.
Design
A retrospective cohort study. Subjects: Individuals from the SICCA cohort (n = 3514).
Methods
A retrospective analysis to examine relationships between dry eye (DE) symptoms and signs and serologic status, including SSA (SSA+ Sjögren disease [SjD], SSA- SjD, non-SjD) and Ig (G, A, M) levels (low, normal, and high). Main Outcome Measures: Univariate analyses using analysis of variance and chi-square tests examined differences in ocular profiles by serologies. Multivariable analyses were then performed to account for potential confounding variables, including other serological measures.
Results
The mean age of the SICCA cohort was 53 ± 13 years, with the majority identifying as female (91%, n = 3185) and White (54%, n = 1894). The presence of SSA impacted ocular profiles, with the SSA+ SjD group reporting less severe symptoms compared with the SSA- SjD and non-SjD groups (spontaneous pain: 2.61 ± 2.83 vs. 3.39 ± 3.01 vs. 3.52 ± 3.09, P < 0.001), but more frequently having ocular signs (low tear production: 57% vs. 52% vs. 28%, P < 0.001; ocular surface staining [OSS]: 83% vs. 69% vs. 35%, P < 0.001). Immunoglobulin levels showed a similar pattern, with the high IgG level group reporting less severe ocular symptoms in the SjD (spontaneous pain: 2.41 ± 2.82 vs. 3.10 ± 2.91 vs. 3.40 ± 2.96; P < 0.001 and P < 0.05) and non-SjD (spontaneous pain: 2.09 ± 2.35 vs. 3.58 ± 3.11 vs. 3.85 ± 3.11; P < 0.001) groups but more severe signs (SjD group: low tear production: 60% vs. 53% vs. 49%; OSS: 88% vs. 72% vs. 70%; P < 0.001) compared with the normal and low-level groups. A similar pattern was noted for IgA levels. Most associations remained significant when considered concomitantly.
Conclusions
Ocular manifestations of DE are influenced by serological factors. Specifically, SSA+ and high IgG and IgA status align with a disease picture of clinical signs of DE disease out of proportion to pain symptoms, while SSA- and low and normal IgG and IgA status align with a DE disease picture of symptoms that outweigh signs. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Miami Miller School of Medicine, Miami, Florida.
- Department of Ophthalmology, Miami Veterans Affairs Medical Center, Miami, Florida.
- Bascom Palmer Eye Institute, University of Miami, Miami, Florida.
- Shantilal Shanghvi Cornea Institute, L.V. Prasad Eye Institute, Hyderabad, India.
- Nova Southeastern University College of Osteopathic Medicine, Davie, Florida.
- Penn State University College of Medicine, Hershey, Pennsylvania.
Förderung
- National Eye Institute
- Sjogrens Syndrome Foundation
- Research to Prevent Blindness
- U.S. Department of Veterans Affairs
- Health Services Research and Development
- Research and Development
- Clinical Science Research and Development
- National Institutes of Health
Zitieren
APA
Shields, C., Donthineni, P. R., Muralidhar, R., Bhatt, S., Karakoleva, E. V., Baer, A., Fox, R., McCoy, S. S., & Galor, A. (2025). Serological Influences on Dry Eye: Insights from the Sjögren's International Collaborative Clinical Alliance. Ophthalmology Science, 5(6), 100843. https://doi.org/10.1016/j.xops.2025.100843
Vancouver
Shields C, Donthineni PR, Muralidhar R, Bhatt S, Karakoleva EV, Baer A, et al. Serological Influences on Dry Eye: Insights from the Sjögren's International Collaborative Clinical Alliance. Ophthalmology Science. 2025;5(6):100843. doi:10.1016/j.xops.2025.100843
BibTeX
@article{Shields2025,
author = {Shields, Chloe and Donthineni, Pragnya Rao and Muralidhar, Rohit and Bhatt, Shreya and Karakoleva, Ema V and Baer, Alan and Fox, Robert and McCoy, Sara S and Galor, Anat},
title = {Serological Influences on Dry Eye: Insights from the Sjögren's International Collaborative Clinical Alliance},
journal = {Ophthalmology Science},
year = {2025},
volume = {5},
number = {6},
pages = {100843},
doi = {10.1016/j.xops.2025.100843}
}
EUVIMED